NeuroPace, Inc. (NPCE Quick QuoteNPCE - Free Report) is well-positioned for solid growth, driven by strong RNS adoption, expanding referral networks and AI-driven innovations that enhance efficiency and utilization. The potential IGE indication offers a long-term growth opportunity. However, near-term profitability may be pressured by higher investments and seasonality, while IGE contribution could be delayed due to approval uncertainty, payer coverage expansion and physician adoption, leaving the core business to drive growth.

In the year-to-date period, this Zacks Rank #2 (Buy) company’s shares have lost 8.8% compared with the industry’s 13.4% decline and the S&P 500 Composite’s 4.8% fall.

As a developer of neuromodulation technology for epilepsy, NeuroPace’s core product is the RNS System, a closed-loop, brain-responsive implant that monitors intracranial EEG, detects patient-specific abnormal electrical patterns and delivers targeted stimulation to help prevent seizures. It has a market capitalization of $442.7 million.

The company projects 82.3% growth for 2027 and expects to maintain its strong performance going forward. NeuroPace’s earnings surpassed the Zacks Consensus Estimate in three of the trailing four quarters and missed one, delivering an average surprise of 24.7%.

Image Source: Zacks Investment Research

Factors Favoring NPCE’s Growth

Core RNS Business Driving Sustained Momentum: NeuroPace continues to strengthen its position in the epilepsy treatment market through solid execution of its core RNS (Responsive Neurostimulation) business. The company delivered 25% revenue growth in 2025, with fourth-quarter revenues rising 24% year over year, driven by 26% growth in RNS System sales. Management emphasized sustained momentum across key operating metrics, including record highs in prescribers, accounts and patient pipeline, reflecting strong adoption and utilization, particularly in Level 4 epilepsy centers.

Growth is further supported by expanding community referral pathways and improved patient funnel management, enabling more efficient conversion from identification to implant. The company expects this foundation to support 20%-22% core RNS growth in 2026 and reiterated confidence in sustaining at least 20% long-term growth within the existing adult focal epilepsy indication. Continued investments in salesforce expansion, incentive structures and nurse navigators are expected to further enhance procedural volumes and drive consistent top-line growth as the commercial engine scales.

Indication Expansion Unlocking a Large Untapped Market: A major catalyst for NeuroPace is the potential expansion of the RNS System into idiopathic generalized epilepsy (IGE), an underserved patient population. NeuroPace submitted its PMA supplement in December 2025, supported by strong NAUTILUS trial results demonstrating a 77% median reduction in seizure frequency and a favorable safety profile. The FDA has accepted the submission and initiated a 180-day review process, with constructive engagement supported by Breakthrough Device Designation. While 2026 guidance excludes any contribution from IGE, management highlighted this opportunity as a potential “meaningful new chapter” for the company. If approved, the expansion would leverage existing clinical infrastructure and physician familiarity with the RNS platform, enabling efficient adoption. This creates a substantial incremental growth vector beyond the core focal epilepsy market, reinforcing NeuroPace’s long-term growth outlook and potential to broaden its leadership in personalized neuromodulation.

AI-Driven Innovation and Product Pipeline Enhancing Adoption: NeuroPace is advancing a suite of AI-driven tools and platform enhancements designed to improve physician workflow, increase efficiency and unlock greater value from its extensive intracranial EEG dataset. The Seizure ID tool, submitted for FDA approval and expected in the first half of 2026, is designed to rapidly analyze patient data, identify seizure activity and reduce clinician review time, addressing a key workflow bottleneck. In parallel, the company is progressing remote care capabilities that will allow physicians to adjust therapy settings during telehealth visits, expanding access and increasing physician capacity. These initiatives are supported by a transition to a cloud-based clinician platform, enabling faster deployment and scalability of software solutions. Development of a foundation AI model leveraging over 24 million EEG recordings and extensive clinical experience aims to drive personalized treatment optimization and improved patient outcomes. Together, these innovations position NeuroPace to increase system utilization, enhance clinician productivity and create a scalable, data-driven neuromodulation platform.

Factors That May Offset the Gains for NPCE

Near-Term Earnings Headwinds and Seasonality: Despite strong revenue growth, NeuroPace is intentionally ramping up investments across its commercial organization and research and development initiatives, which are expected to weigh on near-term profitability. The company guided 2026 adjusted EBITDA to a loss of $9 million-$10 million, reflecting investment intensity. Operating expenses are front-loaded, with slightly more than half of annual spend in the first half, caused by expanded commercial hiring, marketing and nurse navigator programs.

Management highlighted typical seasonality, with revenues expected at $21 million-$22 million in the first quarter of 2026 and moderating growth in the first half before re-accelerating later in the year. The DIXI Medical partnership ended in December 2025, removing a prior revenue stream and creating a tougher year-over-year comparison. Together, these factors point to weaker near-term profitability and operating metrics despite strong 2025 execution and two consecutive quarters of positive adjusted EBITDA, which may weigh on investor sentiment in early 2026.

IGE Approval and Coverage Ramp May Take Time to Monetize: NeuroPace’s IGE PMA supplement, submitted in December 2025 and now under FDA review with a 180-day clock, is progressing with agency dialogue and a planned mid-cycle interaction, but approval timing remains uncertain. While the NAUTILUS data demonstrated clinically meaningful outcomes — including a 77% median seizure reduction at 18 months and a favorable safety profile — the company is awaiting regulatory clearance. Management emphasized that even with approval, revenue contribution will not be immediate. NPCE will need to execute physician training, referral pathway expansion and broader market education across the referring community before volumes can scale. Reflecting these realities, the 2026 revenue guidance of $98-$100 million excludes any contribution from IGE. As a result, even if approved around mid-2026, there is likely to be a lag between approval, coverage build-out and revenue contribution, leaving the core RNS franchise to drive growth in the near term.

NeuroPace, Inc. Price

NeuroPace, Inc. price | NeuroPace, Inc. Quote

Estimate Trend

NeuroPace has been witnessing a positive estimate revision trend for 2026. Over the past 60 days, the Zacks Consensus Estimate for its loss has narrowed by 14 cents to 51 cents per share.

The Zacks Consensus Estimate for 2026 revenues is pegged at $98.8 million, indicating a 1.2% decrease from the year-ago reported numbers.

Other Key Picks

Some other top-ranked stocks from the broader medical space are Phibro Animal Health (PAHC Quick QuotePAHC - Free Report) , GE HealthCare Technologies (GEHC Quick QuoteGEHC - Free Report) and Cardinal Health (CAH Quick QuoteCAH - Free Report) .

Phibro Animal Health, currently sporting a Zacks Rank #1 (Strong Buy), reported second-quarter fiscal 2026 adjusted earnings per share (EPS) of 87 cents, which surpassed the Zacks Consensus Estimate by 27.1%. Revenues of $373.9 million beat the Zacks Consensus Estimate by 4.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.

PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12.4% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 20.1%.

GE HealthCare Technologies, currently carrying a Zacks Rank #2, reported fourth-quarter 2025 adjusted EPS of $1.44, which surpassed the Zacks Consensus Estimate by 0.7%. Revenues of $5.7 billion beat the Zacks Consensus Estimate by 1.9%.

GEHC has an estimated long-term earnings growth rate of 9.1% compared with the industry’s 12.4% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 7.5%.

Cardinal Health, currently carrying a Zacks Rank #2, reported a second-quarter fiscal 2026 adjusted EPS of $2.63, which surpassed the Zacks Consensus Estimate by 10%. Revenues of $65.6 billion beat the Zacks Consensus Estimate by 0.9%.

CAH has an estimated long-term earnings growth rate of 15% compared with the industry’s 9.2% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 9.3%.